logo

Royality Med Pharmaceuticals

Royality Med's mission is to fast-track the early stage of drug discovery using our predictive models of the human brain for therapeutic success. Many neurodevelopmental diseases do not have treatments due to a lack of a-priori knowledge of the underlying biology. Royality Med's technology is able to model these diseases to help enable the discovery of new targets and drugs, de-risking the current failure-prone cumbersome approach.
For inquiries, please contact us at
E-mail: info@royalitymed.com
mobile-logo
 

Our Focus

We aspire to translate science into survival by developing new immunotherapies

Royality Med's (RMP) is a clinical-stage biopharmaceutical company focused on developing a new class of proprietary molecules with unique capabilities that can potentially modify and reverse disease progression in patients suffering from devastating neurodegenerative and autoimmune diseases.

The company has created two families of new chemical entities. These molecules have been created through rational drug design to modulate specific receptors and physiological pathways in the body, which are validated targets in many serious diseases. With a multi-pronged mechanism of action (MOA), these NCEs are well positioned as first-in-class disease-modifying therapeutic drug candidates for many diseases, which currently have no cure.

Driven by eminent global researchers in science and biotechnology, Royality Med's has assembled a highly experienced and expert management team, supported by clinical and scientific advisory boards, to successfully develop these pharmaceutical drug product candidates.

We are in pursuit of gene therapy cures for patients living with rare and devastating genetic diseases.

We are pursuing bold science to set the breakthrough bar higher across therapeutic areas.

Oncology
Taking inspiration from our heritage of redefining standards of care in the treatment of solid tumors, our researchers continue to solve complex scientific problems on behalf of patients everywhere.
Hematology
With the delivery of many transformational firsts in hematology, we remain committed to breaking ground across a spectrum of diseases with high unmet need.
Immunology
We are working to deliver meaningful solutions that address unmet needs in dermatology, gastroenterology, pulmonology and rheumatology.
Cardiovascular
We are building on our 70-year legacy of discovering and delivering paradigm-changing medicines, leveraging our experience and expertise formed over the past several decades to take cardiovascular research to the next level.
Neuroscience
We are dedicated to championing the needs and experiences of people living with neurological and psychiatric diseases through developing disease-modifying, as well as symptomatic therapies.
Antibody-drug conjugates
Antibody-drug conjugates are engineered to deliver therapeutics to targeted locations. They do so by tethering therapeutic payloads (which can include protein degraders, immune stimulators, cytotoxic drugs, and oligonucleotides) via a linker to monoclonal antibodies, which act as honing mechanisms.

I would like to learn about Royality Med’s Pharmaceuticals discoveries to treat genetic diseases.


YES, TELL ME MORE